ASTM

ASTM International

InternationalInternationalStandards body

Consensus standards body; author of E2500, the risk- and science-based approach to specification, design, and verification of manufacturing systems.

Browse the standards library →Official site ↗

WHAT ASTM COVERS

ASTM International develops voluntary consensus standards across many industries. In pharmaceutical manufacturing its most consequential contribution is E2500, the guide to specification, design, and verification of manufacturing systems and equipment, which reframed commissioning and qualification.

WHERE IT SITS INTERNATIONALLY

E2500 is the technical foundation of modern risk-based commissioning and qualification, and is referenced throughout ISPE Baseline Guide Vol. 5. Its logic runs parallel to ICH Q9 risk management and ICH Q8 design space thinking — the same idea that effort should follow risk to the patient, applied to engineering verification instead of formulation.

HOW ITS REQUIREMENTS BITE

ASTM standards are voluntary and ASTM performs no certification or inspection. E2500 gained influence because regulators accepted its logic — risk- and science-based verification focused on what affects product quality — and because ISPE built its Commissioning and Qualification guidance around the same approach.

WHAT ASTM PUBLISHES

  1. 01ASTM E2500 — specification, design, and verification of pharmaceutical manufacturing systems and equipment
  2. 02E2476 and related standards on risk assessment in manufacturing
  3. 03Standards for materials, testing methods, and equipment across sectors
  4. 04Terminology standards used in pharmaceutical engineering

WHAT PRACTITIONERS GET WRONG

  • E2500 does not replace EU GMP Annex 15 — it is an approach for satisfying it more intelligently, and Annex 15 still sets the qualification expectation.
  • Its leverage comes from using vendor documentation and commissioning as verification evidence, where that evidence is assessed and justified rather than assumed.
  • It requires subject matter experts to define what evidence is adequate, with quality approving the approach rather than re-executing the testing.
  • Applying it as a relabelling exercise — renaming IQ/OQ documents without the underlying risk assessment — delivers none of the benefit and is visible to an inspector.
  • The critical-aspects and critical-quality-attribute linkage is what makes the scope defensible; without it, "risk-based" reads as "we tested less".

ASTM STANDARDS SPEQ DECODES · 1

ASTM E2500
Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment

DISCIPLINES IN ASTM’S REMIT

GEPGood Engineering Practice
Weekly Briefing

Track ASTM — and every regulator that matters

New rules, guidance, enforcement, and inspection signals from ASTM International and its peers worldwide, distilled into the free Weekly GxP Briefing.

Read a past issue →